Leukaemia ERR at 100 mGy exposure by subtype and by study
| Study | Non-CLL | AML | CML | CLL |
|---|---|---|---|---|
| Current study | 0.09 | 0.22 | 0.29 | −0.03 |
| (95% CI −0.17 to 0.65) | (95% CI −0.19 to 1.2) | (95% CI <0 to 2.6) | (95% CI −0.16 to 0.74) | |
| 264 decedents | 150 decedents | 52 decedents | 74 decedents | |
| LCCS3 4 | 0.26 | NR | NR | −0.20 |
| (95% CI <−0.10 to 1.03) | (95% CI <0 to 1.4) | |||
| 184 decedents | 43 decedents | |||
| 15-country study*7 30 | 0.196 | −0.41 | 1.0 | −0.17 |
| (90% CI −0.026 to 0.59) | (90% CI −0.76 to 0.17) | (90% CI −0.086 to 4.02) | (95% CI −0.89 to 0.40) | |
| 196 decedents | 81 decedents | 45 decedents | 47 decedents | |
| Three-country study31 | 0.22 | 0.34 | 1.1 | −0.09 |
| (90% CI 0.013 to 0.57) | (90% CI <0 to 1.49) | (90% CI 0.29 to 3.09) | (90% CI <0 to 0.73) | |
| 119 decedents | 32 decedents | 28 decedents | 27 decedents | |
| NRRW6 | 0.17 | 0.12 | 0.33 | <−0.19 |
| (90% CI 0.006 to 0.43) | (90% CI −0.12 to 0.65) | (90% CI 0.04 to 0.93) | (90% CI <−0.19 to 0.12) | |
| 198 decedents | 102 decedents | 44 decedents | 69 decedents | |
| LSS†26 | 0.47 | 0.43 | 0.64 | NR |
| (90% CI 0.35 to 0.64) | (90% CI 0.27 to 0.66) | (90% CI 0.30 to 1.37) | ||
| 310 decedents‡ | 124 decedents | 58 decedents |
*AML and CLL results were calculated using a log-linear relative risk model of the form RR(d)=exp(βd) and ERR=RR−1.
†Based on a linear ERR model without effect modification of the form ERR(d)=βd.
‡Also included seven CLL cases and 121 leukaemias not specified as AML or CML.
AML, acute myeloid leukaemia; CML, chronic myeloid leukaemia; CLL, chronic lymphocytic leukaemia; ERR, excess relative risk; LCCS, NIOSH Leukaemia Mortality Case control Study; LSS, Life-Span Study of Japanese Atomic Bomb Survivors; NC, not calculable; NR, not reported; NRRW, UK National Registry of Radiation Workers.